Immuron Ltd

Immuron Ltd (NASDAQ:IMRN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 19 items for IMRN at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-08-28, rated 7/10. Across its 19 most recent items scored 7 or higher, the top rating is 9/10, with 7 rated 8 or above. Recent SEC coverage for IMRN spans 6-K.

Recent high-impact activity:

• Immuron FY26 Preliminary Results: Record A$7.7M Sales, Loss Narrows 26%, Cash at A$9.0M (2026-08-28)
• Immuron Investor Presentation Maps Strategic Reset, FY26 Sales of A$7.7M, and IMM-529 Partnership Upside (2026-07-27)
• Immuron Investor Presentation Highlights FY26 Sales Growth, Cash Runway, and Partnering Strategy for CDI Asset (2026-07-20)
• Immuron Posts 6% FY26 Sales Growth, Fourth Straight Quarter of Gains (2026-07-16)
• Immuron Advances IMM-529 Partnering Strategy with Pullan Consulting Engagement (2026-07-06)

Insider Transactions

IMRN files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.